Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, ...
FDA Drug Recall #D-0739-2026 - Class III, July 16, 2026
Recall Summary
| Recall Number | D-0739-2026 |
| Classification | Class III, Low risk |
| Date Initiated | July 16, 2026 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Ascend Laboratories, LLC |
| Location | Bedminster, NJ |
| Product Type | Drugs |
| Quantity | 936 cartons x 12 x 3 x 10 (in blister pack) |
Product Description
Dabigatran Etexilate Capsules, 75 mg, 30-count (3x10) blister pack further packaged in a carton, Rx only, Manufactured by: Alkem Laboratories Ltd., Mumbai, INDIA, Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268, NDC 0904-7253-04.
Reason for Recall
Failed impurity/degradation specification: an OOS result observed in Related substance test analysis w.r.t Impurity II, Impurity III and Total impurities for 12-month stability
Distribution Pattern
USA Nationwide
Lot / Code Information
Lot: 25141586, Exp. April 30, 2027.
Other Recalls from Ascend Laboratories, LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0738-2026 | Class III | Dabigatran Etexilate Capsules, 75 mg, 60-count ... | Jul 16, 2026 |
| D-0737-2026 | Class III | Dabigatran Etexilate Capsules, 150 mg, 60-count... | Jul 16, 2026 |
| D-0712-2026 | Class II | Amlodipine and Olmesartan Medoxomil Tablets, 10... | Jul 8, 2026 |
| D-0735-2026 | Class III | Dabigatran etexilate Capsules, 110 mg, 60-count... | Jun 30, 2026 |
| D-0736-2026 | Class III | Dabigatran etexilate Capsules, 150 mg, 20-count... | Jun 30, 2026 |
Frequently Asked Questions
Nitrosamines are probable human carcinogens, they can increase cancer risk with long-term exposure above certain thresholds, but they do not cause immediate harm from taking a single dose. The FDA calculates an acceptable daily intake (ADI) for each nitrosamine compound, and recalls are triggered when levels exceed this threshold. If you have been taking a recalled product, the FDA generally advises against abruptly stopping your medication (especially for critical conditions like blood pressure or diabetes) until you consult your doctor. The incremental cancer risk from short-term exposure is very small.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications, even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications, use a drug take-back program.